Affordable Access

Access to the full text

NHERF1/EBP50 as a Target for Modulation of MRP Function in HepG2 Cells

Authors
  • kawase, atsushi
  • hirosoko, miho
  • sugihara, yuka
  • koyama, yunosuke
  • fukae, ayaka
  • shimada, hiroaki
  • iwaki, masahiro
Publication Date
Mar 08, 2021
Identifiers
DOI: 10.3390/ph14030239
OAI: oai:mdpi.com:/1424-8247/14/3/239/
Source
MDPI
Keywords
Language
English
License
Green
External links

Abstract

As increased expression and activities of efflux transporters (ETs) often cause drug resistance in cancers, we tried modulating ET activity in cancer cells, using scaffold proteins such as ezrin/radixin/moesin (ERM) proteins, and Na+/H+ exchanger regulatory factor-1 (NHERF1)/ERM-binding phosphoprotein of 50 kDa (EBP50). To see whether EBP50 modulated ET activities in human liver cancer HepG2 cells, we used EBP50 siRNA and a designed TAT-PDZ1 peptide. The EBP50 knockdown (EBP50KD) cells had significantly higher intracellular accumulations of Rho123 and carboxy-dichlorofluorescein (CDF), but not H33342 (i.e., the respective substrates of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP), and breast cancer resistance protein (BCRP)), compared with control HepG2, suggesting that EBP50 knockdown in HepG2 cells decreased activity of P-gp and MRP but not BCRP. Treatment with TAT-PDZ1 peptide (&gt / 1 pM) resulted in significantly higher CDF accumulation in HepG2 cells, which persisted for ≥180 min after TAT-PDZ1 peptide treatment. These results imply that EBP50 can modulate ET activities. To our knowledge, this is the first report on using a competitive peptide to modulate interactions between MRP and EBP50.

Report this publication

Statistics

Seen <100 times